Post
ESCMID 2024: Long-acting injectables for HIV prevention
At the 34th European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Global (formerly ECCMID) conference in Barcelona, Spain, the …
UK report warns that economic instability is threatening life sciences sector
A report published by Medicines Discovery Catapult (MDC) is urging the UK life sciences sector to boost investment following findings …
Zenas raises $200m to advance autoimmune antibody therapy
US-based Zenas BioPharma has raised $200m in a Series C round to support the clinical development of its lead candidate, …
OCT Europe: Data governance guidance provides much-needed clarity
The introduction of a section dedicated to data governance in the European good clinical practice (GCP) guidance provides much-needed clarity. In …
Uproleselan’s failed Phase III AML trial shakes up GlycoMimetics’ future
On 6 May 2024, US-based biotech GlycoMimetics announced that its E-selectin inhibitor candidate uproleselan had failed to improve the overall …
Phanes Therapeutics signs clinical supply agreement with Roche
US-based biopharmaceutical company Phanes Therapeutics has announced a clinical supply agreement with Roche for a combination therapy study. The collaboration will …
ESCMID 2024: Long-acting injectables for HIV prevention
At the 34th European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Global (formerly ECCMID) conference in Barcelona, Spain, the …
UK report warns that economic instability is threatening life sciences sector
A report published by Medicines Discovery Catapult (MDC) is urging the UK life sciences sector to boost investment following findings …
Zenas raises $200m to advance autoimmune antibody therapy
US-based Zenas BioPharma has raised $200m in a Series C round to support the clinical development of its lead candidate, …
OCT Europe: Data governance guidance provides much-needed clarity
The introduction of a section dedicated to data governance in the European good clinical practice (GCP) guidance provides much-needed clarity. In …
Uproleselan’s failed Phase III AML trial shakes up GlycoMimetics’ future
On 6 May 2024, US-based biotech GlycoMimetics announced that its E-selectin inhibitor candidate uproleselan had failed to improve the overall …
Pfizer reports fatality in Phase II DMD gene therapy study
Pfizer has reported the death of a patient in the Phase II DAYLIGHT study of experimental gene therapy, fordadistrogene movaparvovec, …
Neurogene reports initial data from Rett syndrome gene therapy trial
Neurogene has shared initial safety and tolerability results from its ongoing Phase I/II clinical trial of NGN-401, a gene therapy …
RION doses first subject in Phase IIa diabetic foot ulcer therapy trial
Regenerative medicine company RION has dosed the first subject in the Phase IIa clinical trial of its purified exosome product …
LEO Pharma reports positive data from Phase III plaque psoriasis trial
LEO Pharma has announced positive data from the Phase III clinical trial of Enstilar (LEO 90100) in Chinese adult patients …